Physician profile
Sathiyendran Poobalasingham
NPI 1639210222
$1,131.50
in general payments reported to CMS, 2019-2025
14 companies · $42.63 in 2025
The $42.63 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $111 · 2021: $169 · 2022: $71.44 · 2023: $201 · 2024: $365 · 2025: $42.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530 · Education: $78.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.51 |
| Education | $78.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $170.22 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $153.00 | 2019-2024 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $146.35 | 2021-2024 | Acthar |
| Travere Therapeutics, INC. | $140.25 | 2022-2025 | Filspari, Thiola |
| Astrazeneca Pharmaceuticals LP | $138.34 | 2019-2024 | Farxiga |
| Vifor Pharma, INC. | $90.15 | 2019-2023 | Korsuva, Veltassa |
| Akebia Therapeutics INC | $84.54 | 2020-2024 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $66.95 | 2019-2024 | Jynarque |
| Ardelyx, INC. | $43.71 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $24.54 | 2023 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $23.49 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.72 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.55 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sathiyendran Poobalasingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.